篇名

美國法下原開發藥廠與學名藥廠在藥品警告責任的競合與發展   免費試閱

並列篇名

The Concurrent Relationship between Brand Name and Generic Drug Manufacturer’s Duty to Warn under the US Law System

作者
中文摘要

美國法下,當已知某藥品有潛在危險,卻因製造人未在標示給予適當警告,使消費者使用新藥或學名藥後引起強烈副作用,製造人應負藥品警告責任。然購買新藥者得對原開發藥廠請求賠償,卻因藥事法阻卻學名藥廠產品責任,使得購買學名藥者無法向其提起訴訟。法院得否擴張產品責任範圍,使購買學名藥者轉向原開發藥廠求償?本文從美國藥事法與侵權法規定與法律原則出發,梳理法院判例,分析本議題下美國藥事法和藥品責任的競合與發展。

英文摘要

Under US law, the manufacturer bears the duty to warm when a drug is known to be potentially dangerous. Therefore, if the consumer still takes the drug and come with serious side effects because there don’t have any proper warning on the label, the manufacturer should take the responsibility. Under the case law, those who purchase brand name drugs may request compensation from the manufacturer in the aforementioned situation. However, blaming the United States Federal Food, Drug, and Cosmetic Act preempt the product liability of generic drug manufacturer, the person who purchases the generic drug cannot file a lawsuit against the generic drug manufacturer. Could the court expand the scope of product liability so that those who purchase the generic drug can turn to the brand name drug manufacturer for compensation? This article starts from the legal principles and provisions of the US Pharmaceutical Law and Tort Law, sorts out the court’s precedent and jurisprudence, and analyzes the concurrent relationship between the brand name and generic drug manufacturer’s duty to warn under the US Law System.

起訖頁

148-168

出版單位
DOI

10.3966/241553062019110037013  複製DOI  DOI查詢

QRCode

數位整合服務
產品服務
讀者服務專線:+886-2-23756688   傳真:+886-2-23318496   地址:臺北市館前路28號7樓

Copyright © 元照出版 All rights reserved. 版權所有,禁止轉貼節錄
TOP